OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Protein–protein interactions: developing small-molecule inhibitors/stabilizers through covalent strategies
Bobby Lucero, Karol R. Francisco, Lawrence J. Liu, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 7, pp. 474-488
Open Access | Times Cited: 13
Bobby Lucero, Karol R. Francisco, Lawrence J. Liu, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 7, pp. 474-488
Open Access | Times Cited: 13
Showing 13 citing articles:
Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety
Renshuai Zhang, Songbo Xie, Jie Ran, et al.
Journal of Cellular Physiology (2024) Vol. 239, Iss. 5
Closed Access | Times Cited: 9
Renshuai Zhang, Songbo Xie, Jie Ran, et al.
Journal of Cellular Physiology (2024) Vol. 239, Iss. 5
Closed Access | Times Cited: 9
SF3B1: From core splicing factor to oncogenic driver
Pedro Bak‐Gordon, James L. Manley
RNA (2025), pp. rna.080368.124-rna.080368.124
Open Access
Pedro Bak‐Gordon, James L. Manley
RNA (2025), pp. rna.080368.124-rna.080368.124
Open Access
The expanding repertoire of covalent warheads for drug discovery
Namrashee V. Mehta, Mariam S. Degani
Drug Discovery Today (2023) Vol. 28, Iss. 12, pp. 103799-103799
Closed Access | Times Cited: 17
Namrashee V. Mehta, Mariam S. Degani
Drug Discovery Today (2023) Vol. 28, Iss. 12, pp. 103799-103799
Closed Access | Times Cited: 17
Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases
Priyanka Dey Talukdar, Urmi Chatterji
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 17
Priyanka Dey Talukdar, Urmi Chatterji
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 17
Decaging-to-labeling: Development and investigation of quinone methide warhead for protein labeling
Fuhu Guo, Shengnan Qin, Ziqi Liu, et al.
Bioorganic Chemistry (2024) Vol. 143, pp. 107088-107088
Closed Access | Times Cited: 3
Fuhu Guo, Shengnan Qin, Ziqi Liu, et al.
Bioorganic Chemistry (2024) Vol. 143, pp. 107088-107088
Closed Access | Times Cited: 3
Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins
Xiaoyu Zhang, Benjamin F. Cravatt
Annual Review of Cancer Biology (2024) Vol. 8, Iss. 1, pp. 155-175
Open Access | Times Cited: 3
Xiaoyu Zhang, Benjamin F. Cravatt
Annual Review of Cancer Biology (2024) Vol. 8, Iss. 1, pp. 155-175
Open Access | Times Cited: 3
Application of A lphaF old models in evaluating ligandable cysteines across E 3 ligases
Patrick Koldenhof, Martijn P. Bemelmans, B.K. Ghosh, et al.
Proteins Structure Function and Bioinformatics (2024) Vol. 92, Iss. 7, pp. 819-829
Closed Access | Times Cited: 2
Patrick Koldenhof, Martijn P. Bemelmans, B.K. Ghosh, et al.
Proteins Structure Function and Bioinformatics (2024) Vol. 92, Iss. 7, pp. 819-829
Closed Access | Times Cited: 2
Sesamolin serves as an MYH14 inhibitor to sensitize endometrial cancer to chemotherapy and endocrine therapy via suppressing MYH9/GSK3β/β-catenin signaling
Yibin Lin, Xiaohong Chen, Linping Lin, et al.
Cellular & Molecular Biology Letters (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 2
Yibin Lin, Xiaohong Chen, Linping Lin, et al.
Cellular & Molecular Biology Letters (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 2
Covalent fragment approaches targeting non-cysteine residues
Noémi Csorba, Péter Ábrányi‐Balogh, György M. Keserű
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 802-816
Open Access | Times Cited: 5
Noémi Csorba, Péter Ábrányi‐Balogh, György M. Keserű
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 802-816
Open Access | Times Cited: 5
Targeted Reversible Covalent Modification of a Noncatalytic Lysine of the Krev Interaction Trapped 1 Protein Enables Site-Directed Screening for Protein–Protein Interaction Inhibitors
Karol R. Francisco, Jessica Bruystens, Carmine Varricchio, et al.
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 11, pp. 1651-1658
Open Access | Times Cited: 3
Karol R. Francisco, Jessica Bruystens, Carmine Varricchio, et al.
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 11, pp. 1651-1658
Open Access | Times Cited: 3
Unity Is Strength: The Mutual Alliance between CFTR and SLC26A6 as Therapeutic Opportunity in Cystic Fibrosis
Marilena Pariano, Cinzia Antognelli, Luigina Romani, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 367-367
Open Access
Marilena Pariano, Cinzia Antognelli, Luigina Romani, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 367-367
Open Access
Discovery of Pyrazolo[1,5-a]pyrimidine Derivatives Targeting TLR4−TLR4* Homodimerization via AI-Powered Next-Generation Screening
Yaoyao Jiang, Shuai-Ting Yan, Shan-Zhuo Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 280, pp. 116945-116945
Closed Access
Yaoyao Jiang, Shuai-Ting Yan, Shan-Zhuo Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 280, pp. 116945-116945
Closed Access
Exploring Small Molecules Targeting Protein–Protein Interactions (PPIs): Advancements and Future Prospects
Sachin Patil
Pharmaceuticals (2023) Vol. 16, Iss. 12, pp. 1644-1644
Open Access | Times Cited: 1
Sachin Patil
Pharmaceuticals (2023) Vol. 16, Iss. 12, pp. 1644-1644
Open Access | Times Cited: 1
